Neumora Therapeutics Inc (NMRA) stock saw a decline, ending the day at $2.12 which represents a decrease of $-0.04 or -1.85% from the prior close of $2.16. The stock opened at $2.18 and touched a low ...

Neumora Therapeutics’ phase 3 fail was worse than analysts feared. | Neumora Therapeutics’ phase 3 fail was worse than ...

In terms of valuation, Neumora Therapeutics Inc’s market capitalization stands at $348.98 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s ...

Neumora will provide additional updates on the development of the drug at an industry conference later this month. (Reporting by Sriparna Roy, Sneha S K and Kamal Choudhury in Bengaluru; Editing ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Neumora ...

Neumora Therapeutics’ big bet on a new era of neuroscience has delivered an age-old result. The first of three late-stage readouts on Neumora’s lead drug candidate has ended in failure ...

Neumora Therapeutics ( NMRA) shares crashed 80% to an all-time low Thursday when the biopharmaceutical firm announced that a late-stage study of its experimental treatment for depression did not meet ...

Neumora Therapeutics Inc.’s stock tumbled 81% Thursday after the clinical-stage biotech said a late-stage trial of a treatment for major depressive disorder failed to meet its main goals.

Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 study for major depressive disorder, causing an 80% stock drop yesterday.

Jan 2 (Reuters) - Neumora Therapeutics' (NMRA.O), opens new tab shares tumbled more than 80% on Thursday after its experimental depression drug failed to reduce symptoms such as sadness and ...

Neumora's navacaprant Phase 3 KOASTAL-1 Study failed to meet primary and key secondary endpoints for major depressive disorder. Navacaprant and placebo showed similar outcomes: -12.5 on MADRS and ...